Form 4: Exelixis Director David Johnson Acquires Options in Latest SEC Filing

David Johnson, a director at Exelixis, acquired options to purchase 42,767 shares of common stock at an exercise price of $21.69, according to a recent SEC Form 4 filing.

Summary

• On May 31, 2024, David Edward Johnson, a director of Exelixis, Inc., acquired options to purchase 42,767 shares of Exelixis common stock.
• The exercise price for these options is $21.69.
• The options were granted pursuant to the Exelixis, Inc. 2017 Equity Incentive Plan.
• The options are exercisable immediately, subject to repurchase provisions, and will vest as to 100% of the shares on the first anniversary of the grant date, contingent upon Mr. Johnson's continuous service.
• Mr. Johnson is deemed to hold these securities for the benefit of Caligan Partners Master Fund LP and managed accounts to which Caligan Partners LP serves as investment manager.
• Caligan Partners LP may be deemed a director by deputization due to Mr. Johnson's board service.

Sentiment

Score: 6

Explanation: The sentiment is neutral as it reports a standard transaction related to executive compensation. It doesn't indicate any significant positive or negative developments for the company.

Positives

• The grant of options to a director aligns their interests with those of the shareholders.
• The vesting schedule incentivizes continued service and commitment to the company.

Industry Context

This filing is a routine disclosure related to executive compensation and equity ownership, common in the biopharmaceutical industry.

Comparison to Industry Standards

• Option grants are a standard component of executive compensation packages in the biotechnology and pharmaceutical industries.
• Companies like Amgen, Gilead Sciences, and Biogen also utilize equity-based compensation to align executive incentives with shareholder value.
• The vesting schedule and exercise price are typical for such grants.

Stakeholder Impact

• The option grant aligns the director's interests with those of shareholders, potentially encouraging decisions that increase shareholder value.

Key Dates